Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Ash Stevens to Make Cancer Drug Ingredients
May 31, 2004
| A version of this story appeared in
Volume 82, Issue 22
Ash Stevens will manufacture 5-azacitidine, the active ingredient in Pharmion's Vidaza, a recently approved treatment for the blood cancer myelodysplastic syndromes. According to Ash Stevens CEO Stephen A. Munk, his firm developed 5-azacitidine in partnership with its discoverer, the National Cancer Institute. Ash Stevens recently received FDA approval to make bortezomib, the active ingredient in Millennium Pharmaceutical's bone marrow cancer drug Velcade, and Munk expects approval later this year to make clofarabine, the active ingredient in Genzyme's Clofarex, a pediatric leukemia drug.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X